Physician profile
Michael R Magee
NPI 1952306771
$28,194.01
in general payments reported to CMS, 2019-2025
28 companies · $995 in 2025
The $995 reported for 2025 was more than what 90% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $717 · 2020: $186 · 2021: $19K · 2022: $6,052 · 2023: $746 · 2024: $878 · 2025: $995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,618.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,618.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $22,655.78 | 2019-2025 | |
| Abbvie INC. | $1,158.40 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $569.87 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $565.24 | 2021-2025 | |
| Myovant Sciences INC. | $401.71 | 2021-2022 | |
| Gynesonics, INC. | $371.31 | 2022-2023 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Shield Therapeutics INC | $349.30 | 2024-2025 | |
| Biogen, INC. | $339.74 | 2024-2025 | Zurzuvae |
| Pfizer INC. | $291.86 | 2021-2024 | |
| Coopersurgical, INC. | $256.86 | 2021-2025 | Paragard T 380a |
| Exeltis, USA INC. | $174.92 | 2021-2025 | Slynd |
| Daiichi Sankyo INC. | $165.72 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $143.74 | 2019-2024 | |
| Organon LLC | $140.99 | 2022-2025 | Nexplanon, Jada System |
| Minerva Surgical, INC | $97.12 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $85.56 | 2021-2024 | Aptima, Third Wave, Thinprep 2000 Processor |
| Therapeuticsmd, INC. | $82.55 | 2019-2022 | |
| Astellas Pharma US INC | $69.44 | 2019-2024 | Veozah |
| Avion Pharmaceuticals | $67.28 | 2021-2022 | |
| Teleflex LLC | $43.07 | 2025 | Quikclot |
| Millicent US INC | $38.02 | 2024-2025 | Femring, Intrarosa |
| Urovant Sciences INC | $28.35 | 2022 | |
| Agile Therapeutics, INC. | $26.52 | 2021-2022 | |
| Sequel Med Tech, LLC | $17.63 | 2025 | Twiist |
| Amag Pharmaceuticals, INC. | $13.70 | 2019 | |
| Aspira Women'S Health INC | $13.66 | 2022 | |
| Evofem Biosciences, INC. | $13.51 | 2021 | |
| Covidien LP | $12.16 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Magee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.